GleamWall
中文EN

ADCT ADC Therapeutics SA

Pharmaceutical Preparations · NYSE · SEC CIK 1771910 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.8%
TTM net income YoY51.3%
TTM EPS YoY67.4%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-97.7%
Net margin-95.7%
FCF margin-118.5%
EBITDA margin—

Returns

ROE—
ROA-29.8%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets197.4%
Debt / equity—
Current ratio3.05x
Interest coverage-1.58x

Cash quality & payout

Operating cash flow / net income1.24x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$21.72M$19.25M$20.85M$23.06M$16.43M$18.84M$23.03M$16.91M
R&D expense$14.74M$17.37M$19.88M$18.18M$26.80M$30.09M$28.93M$27.10M
SG&A expense$10.74M$9.70M$9.90M$9.46M$8.33M$8.82M$9.96M$9.62M
Operating income-$14.35M-$25.41M-$25.25M-$17.92M-$30.97M-$44.15M-$28.46M-$32.44M
Interest expense$13.73M$13.51M$12.35M$13.01M$13.39M$13.00M$12.23M$11.92M
Pretax income-$25.30M-$16.57M-$32.97M-$6.81M-$40.97M-$55.39M-$38.44M-$31.05M
Income tax$0$0$0-$404,000$0$1.25M$165,000-$321,000
Net income-$25.30M-$16.57M-$32.97M-$6.41M-$40.97M-$56.65M-$38.60M-$30.73M
EBITDA———-$17.92M-$30.97M-$43.78M-$28.12M-$32.09M
EPS (basic)-0.16-0.11-0.21—-0.30-0.50-0.36—
EPS (diluted)-0.16-0.11-0.21—-0.30-0.50-0.36—
Weighted avg. shares (diluted)155.41M155.02M154.14M—136.45M113.74M107.20M—
Balance sheet
Cash & equivalents$189.20M$219.11M$231.01M$261.34M$234.74M$264.56M$194.70M$250.87M
Inventory$5.63M$4.93M$4.78M$4.18M$18.04M$17.76M$17.45M$2.25M
Current assets$238.58M$261.71M$276.77M$306.33M$287.15M$318.75M$257.99M$291.25M
PP&E, net———$0$0$1,000$5.16M$5.08M
Total assets$255.86M$279.38M$291.50M$323.15M$289.76M$321.56M$272.54M$321.98M
Current liabilities$78.12M$86.33M$67.63M$70.16M$62.04M$64.60M$57.79M$80.47M
Short-term debt$7.80M$6.18M$4.63M$3.00M———$0
Total liabilities$505.04M$507.58M$507.87M$508.98M$527.94M$520.75M$510.76M$524.62M
Shareholders' equity-$249.17M-$228.21M-$216.38M-$185.83M-$238.18M-$199.18M-$238.22M-$202.64M
Shares outstanding127.74M127.44M127.17M125.75M112.63M112.50M99.18M98.86M
Cash flow statement
Operating cash flow-$27.88M-$11.81M-$29.71M-$31.12M-$29.63M-$24.09M-$56.33M-$21.85M
Capital expenditure$0$0$32,000$0$0$0$264,000$90,000
Free cash flow-$27.88M-$11.81M-$29.74M-$31.12M-$29.63M-$24.09M-$56.60M-$21.94M
Investing cash flow$0$0-$32,000$659,000$0$0-$264,000-$90,000
Financing cash flow-$2.10M-$99,000-$583,000$57.09M-$198,000$93.78M$271,000-$1.12M
Depreciation & amortization———$0$0$362,000$342,000$341,000
Stock-based compensation$4.09M$4.55M$2.44M$673,000$2.00M$1.81M$2.42M$1.62M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.